KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Current Assets (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Current Assets for 17 consecutive years, with $29.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 1.31% to $29.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $29.4 billion, a 1.31% decrease, with the full-year FY2025 number at $29.4 billion, down 1.31% from a year prior.
  • Current Assets was $29.4 billion for Q4 2025 at Bristol Myers Squibb, down from $35.6 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $35.6 billion in Q3 2025 to a low of $27.1 billion in Q1 2023.
  • A 5-year average of $30.2 billion and a median of $29.8 billion in 2024 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: decreased 18.01% in 2022, then rose 26.91% in 2025.
  • Bristol Myers Squibb's Current Assets stood at $33.3 billion in 2021, then decreased by 18.01% to $27.3 billion in 2022, then grew by 16.49% to $31.8 billion in 2023, then decreased by 6.26% to $29.8 billion in 2024, then dropped by 1.31% to $29.4 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Current Assets are $29.4 billion (Q4 2025), $35.6 billion (Q3 2025), and $30.8 billion (Q1 2025).